Monitor upcoming FDA decisions and PDUFA dates for BBP-418, encaleret, and infigratinib as key catalysts; the $500M buyback provides downside support but watch cash burn rate. EPS miss suggests higher-than-expected operating expenses may pressure near-term sentiment.
BBIO drugs
BBIO drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 8 $67.39entry
- T+1 · 6mo ago −4.02%α −4.25% · $64.68
- T+5 · 6mo ago +3.37%α +1.90% · $69.66
- T+20 · 5mo ago +0.33%α +0.30% · $67.61
- T+60 · 3mo ago +21.78%α +16.94% · $82.07
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BridgeBio reported Q1 2026 revenue of $194.5M (beat $178.6M consensus) driven by $180.6M in Attruby sales, but EPS of -$0.84 missed the -$0.62 consensus. The company announced a $500M buyback and highlighted strong pipeline progress with upcoming NDAs. Mixed results as strong commercial execution is offset by higher costs and EPS miss.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $194.5M, +66.8% YoY, beat $178.6M consensus
- Attruby U.S. net product revenue $180.6M vs $36.7M YoY
- GAAP EPS -$0.84 vs consensus -$0.62 (miss of -35.5%)
- Cash, cash equivalents and marketable securities $940.2M, up from $587.5M at Dec 2025
- Board authorized $500M share repurchase program
- Three NDAs planned: BBP-418 submitted, encaleret in 1H 2026, infigratinib in Q3 2026
Financial Impact
Revenue beat by $15.9M (8.9%), EPS miss by $0.22 (35.5%)
Risk Factors
- Regulatory delays or rejections for pipeline candidates
- Competition from Pfizer's tafamidis (Vyndamax)
- High operating cash burn of $197M in Q1 2026
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290504 |
Track record
38 reports on BBIO
10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $77.36 −1.04% settles Dec 11
- Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
- Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $77.36 +3.22% settles Nov 30
- Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $77.36 +9.23% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $77.36 +13.56% settles Nov 19
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $77.36 +22.21% ▲ +24.28% +27.89% vs SPY
- Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers